Does OSIMERTINIB Cause Central nervous system lesion? 45 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 45 reports of Central nervous system lesion have been filed in association with OSIMERTINIB (TAGRISSO). This represents 0.2% of all adverse event reports for OSIMERTINIB.
45
Reports of Central nervous system lesion with OSIMERTINIB
0.2%
of all OSIMERTINIB reports
2
Deaths
10
Hospitalizations
How Dangerous Is Central nervous system lesion From OSIMERTINIB?
Of the 45 reports, 2 (4.4%) resulted in death, 10 (22.2%) required hospitalization, and 3 (6.7%) were considered life-threatening.
Is Central nervous system lesion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 45 reports have been filed with the FAERS database.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Malignant neoplasm progression (2,920)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
What Other Drugs Cause Central nervous system lesion?
FINGOLIMOD (2,416)
DIMETHYL (1,152)
INTERFERON BETA-1A (978)
NATALIZUMAB (627)
DALFAMPRIDINE (561)
GLATIRAMER (492)
TERIFLUNOMIDE (315)
ADALIMUMAB (229)
OFATUMUMAB (185)
RITUXIMAB (151)
Which OSIMERTINIB Alternatives Have Lower Central nervous system lesion Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN